Event - 02/07/2019 Meet & Match: Precision Medicine – Research, Diagnostics & Therapy Stuttgart, Registration deadline: 01/07/2019, Meet & Match https://www.gesundheitsindustrie-bw.de/en/event/meet-match-precision-medicine
Article - 22/03/2019 Personalised therapies for treating metastasing breast cancer Breast cancer is characterised by broad genetic diversity. Successful treatment is made even more difficult by the fact that, in advanced breast cancer, the properties of metastases often differ significantly from the primary tumour. The Heidelberg CATCH study is now collecting genetic profiles from patients' metastasis tissue samples, which can be used to tailor therapy to individual requirements. If necessary, therapy can subsequently be…https://www.gesundheitsindustrie-bw.de/en/article/news/personalisierte-therapieansaetze-bei-metastasiertem-brustkrebs
Article - 29/01/2019 Targeted RNA editing with the body’s own enzyme activity Completely new possibilities for research and gene therapy became available following the development of the CRISPR/Cas method for targeted modification of the genome. However, treatment with these molecular scissors is not without risk as potential errors are stored in the genome forever. Scientists from Tübingen have developed an alternative method in which the intervention takes place at the RNA level using the body's own enzymes and is…https://www.gesundheitsindustrie-bw.de/en/article/news/targeted-rna-editing-with-the-bodys-own-enzyme-activity
Article - 10/01/2019 Stocktaking and recommendations for action: the BBAW’s fourth gene technology report In the new gene technology report, the interdisciplinary working group of the Berlin-Brandenburg Academy of Sciences (BBAW) takes stock of gene technology developments in Germany during the past few decades, and discusses the societal, legal and ethical challenges associated with these technologies in the future. The report is highly topical due to the controversy surrounding the ruling of the European Court of Justice on CRISPR/Cas9 genome…https://www.gesundheitsindustrie-bw.de/en/article/news/stocktaking-and-recommendations-for-action-the-bbaws-fourth-gene-technology-report
Press release - 29/11/2018 Hattrick in Freiburg Three researchers at the MPI for Immunobiology and Epigenetics receive millions in funding from the European Research Council. Dominic Grün, Nicola Iovino and Ritwick Sawarkar from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg will each be awareded one of the prestigious Consolidator Grants of the European Research Council. This means that 6 million euros in funding will go to fundamental research in Freiburg over the next…https://www.gesundheitsindustrie-bw.de/en/article/press-release/hattrick-in-freiburg
Article - 19/11/2018 Tobacco for health Plants can be used as biofactories to produce valuable active ingredients such as proteins, antibodies, dyes or vaccines. A project called Newcotiana aims to re-position the existent tobacco industry infrastructure. The project partners, including Prof. Dr. Holger Puchta from the Karlsruhe Institute of Technology, use modern breeding methods to develop tobacco varieties with new capabilities.https://www.gesundheitsindustrie-bw.de/en/article/news/tobacco-for-health
Dossier - 28/08/2018 With molecular diagnostics to biomarker-based personalised therapy Diagnosing suitable biomarkers is a prerequisite for tailoring personalised therapies to patient heterogeneity. Genetic tests and genome sequencing play a key role in these diagnoses. Up until now, personalised therapy has achieved the greatest success in the field of oncology. However, personalised treatments are also gaining in importance for treating other diseases. In Baden-Württemberg, the expansion and further development of personalised…https://www.gesundheitsindustrie-bw.de/en/article/dossier/with-molecular-diagnostics-to-biomarker-based-personalised-therapy
Article - 12/07/2018 The role of stem cell dormancy in regeneration and cancer Scientists at the HI-STEM stem cell institute in Heidelberg have shown that the stem cells responsible for replenishing blood cells have the greatest potential of self-renewal of any other stem cells. However, they are normally in a dormant state, and only become active upon exposure to certain stress factors. This protects the genomes of the stem cells from damage that causes leukaemias. The researchers have shown that an oncogene called MYC…https://www.gesundheitsindustrie-bw.de/en/article/news/the-role-of-stem-cell-dormancy-in-regeneration-and-cancer
Article - 26/06/2018 Genome analyses: "Germany lags behind dramatically" Today, around 6,000 genetic diseases can be diagnosed using genetic tests. Genetic testing enables the accurate identification of diseases especially when symptoms are unclear, and also allows statements to be made about disease progression. However, restrictive regulations considerably hinder the use of genetic diagnostics in Germany - and it is patients who pay the price. BIOPRO spoke with Dr. Dr. Saskia Biskup, a human genetics specialist and…https://www.gesundheitsindustrie-bw.de/en/article/news/genome-analyses-germany-lags-behind-dramatically
Article - 29/05/2018 ITAS – Assessing the impact of life science technologies The Karlsruhe Institute for Technology Assessment and Systems Analysis (ITAS) is one of the largest and most renowned institutions in Germany involved in evaluating scientific and technological developments. The institute assesses the impacts and possible effects of new methods from a wide range of scientific fields - including the life sciences. It particularly focuses on controversial disciplines such as synthetic biology, genome editing and…https://www.gesundheitsindustrie-bw.de/en/article/news/assessing-the-impact-of-life-science-technologies
Article - 23/05/2018 Bacteriophages as alternatives to antibiotics Multidrug-resistant bacteria are resistant to many existing antibiotics and can be difficult to treat. There are increasing numbers of them worldwide. Although novel antibiotics are being developed, there are far too few of them to tackle the rise of multidrug-resistant bacteria. In Eastern Europe, doctors have been treating bacterial infections with viruses that infect bacteria, so-called bacteriophages, for almost 100 years. Wolfgang Beyer from…https://www.gesundheitsindustrie-bw.de/en/article/news/bacteriophages-as-alternatives-to-antibiotics
Article - 28/03/2018 New method for analysing epigenetic modifications - in the service of medical progress It is not just genetic factors that influence developmental processes and diseases; it is becoming increasingly evident that epigenetic changes play a major role too. Thanks to a new method developed at the University of Stuttgart, epigenetic processes can now be investigated in living cells.https://www.gesundheitsindustrie-bw.de/en/article/news/new-method-for-analysing-epigenetic-modifications-in-the-service-of-medical-progress
Article - 26/03/2018 Eliciting reliable information from big data with classifiers and multimodal data fusion Prof. Hans A. Kestler knows a great deal about large amounts of data. He heads up the Institute of Medical Systems Biology at the University of Ulm and is constantly inundated with cooperation enquiries from clinicians. On behalf of BIOPRO, Walter Pytlik asked him whether the conditions for using big data more in biomedical research are already largely present. https://www.gesundheitsindustrie-bw.de/en/article/news/eliciting-reliable-information-from-big-data-with-classifiers-and-multimodal-data-fusion
Article - 13/03/2018 “More data does not automatically imply more knowledge“ In Germany, one of the big names in evidence-based medicine is Prof. Dr. rer. nat. Gerd Antes, co-director of Cochrane Germany. In the following interview, Antes talks about the hype surrounding big data, warns against false promises and reminds us about what is taken for granted. https://www.gesundheitsindustrie-bw.de/en/article/news/more-data-does-not-automatically-imply-more-knowledge
Dossier - 06/03/2018 Big data - the big promise of the new digitised world Big data is a widely used buzzword in today's information era. The use of big data in the digital world presents both an opportunity and a risk. Mass data is now used and analysed in almost all areas of life. Even the healthcare sector is undergoing extensive digitisation. https://www.gesundheitsindustrie-bw.de/en/article/dossier/big-data-the-big-promise-of-the-new-digitised-world
Article - 18/01/2018 Medications that target metastasing tumours Tumour metastases are often resistant to the drug that is used to eliminate the primary tumour. Genome-wide analyses of mutation patterns in the primary tumour and its metastases provide information on the aggressiveness of cancer and may help to find the best available means of further treatment. This has been demonstrated by scientists from Heidelberg in a clinical trial on the molecular evolution of renal cancer.https://www.gesundheitsindustrie-bw.de/en/article/news/medications-that-target-metastasing-tumours
Press release - 04/01/2018 CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics CureVac AG, a leading clinical-stage biopharmaceutical company focused on the development of pioneering mRNA therapeutics, and Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company, today announced they have entered into a broad strategic collaboration to jointly discover, develop and commercialize novel messenger RNA (mRNA) therapeutics.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-arcturus-therapeutics-announce-broad-strategic-collaboration-to-advance-next-generation-of-lipid-mediated-mrna-thera
Article - 14/12/2017 Looking at the whole genome raises new questions Research laboratories around the world have long focused on studying the whole human genome. It is hoped that knowing the whole human genome will improve diagnostics and enable more specific therapies. Although genome analysis has not yet reached routine clinical application, whole genome sequencing has already raised many ethical and legal issues - for researchers, physicians and patients.https://www.gesundheitsindustrie-bw.de/en/article/news/looking-at-the-whole-genome-raises-new-questions
Article - 14/08/2017 Saskia Biskup – towards precision medicine Therapeutic success can only be achieved when diagnoses are as precise as possible. Nowadays, genetic analyses can make precise diagnoses for many diseases. And thanks to high-throughput technology, results are available to patients very quickly. Dr. Dr. Saskia Biskup recognised the importance of precision medicine many years ago and went on to found CeGaT GmbH, a company that combines human genetics with high-throughput sequencing. Three…https://www.gesundheitsindustrie-bw.de/en/article/news/saskia-biskup-towards-precision-medicine
Event - 27/11/2017 Meet & Match: Strategies for Drug Discovery: Simulation – Screening – Repurposing Strasbourg, France, Registration deadline: 23/11/2017, Meet & Match https://www.gesundheitsindustrie-bw.de/en/event/drugdiscovery
Press release - 02/06/2017 GATC to be part of Eurofins Group GATC, one of the leading sequencing provider will be a part of the Eurofins Group as of July 2017 to create the leading company in the worldwide sequencing market.https://www.gesundheitsindustrie-bw.de/en/article/press-release/gatc-wird-ein-teil-der-eurofins-gruppe
Article - 04/05/2017 Big data make therapy work better An international team of researchers has shown for acute myeloid leukaemia (AML) that cancer therapy can be personalised using big data. The authors of the study “believe this paper is a step towards validation of genetic techniques as a route to personalised medicine”. https://www.gesundheitsindustrie-bw.de/en/article/news/mit-big-data-genauer-therapieren
Article - 31/03/2017 A novel mechanism of cancer development Epstein-Barr virus (EBV) infections occur in almost all adults worldwide and are a high risk factor for some types of cancer. Researchers from Heidelberg have now come up with a novel mechanism that promotes carcinogenesis involving an EBV protein rather than the genome of the virus. The EBV protein BNRF1 induces the excessive amplification of the centrosomes of the spindle apparatus, and leads to chromosomal instability and inaccurate…https://www.gesundheitsindustrie-bw.de/en/article/news/a-novel-mechanism-of-cancer-development
Article - 07/02/2017 Designer proteins as beacons of hope for pharmaceutical and biotechnological applications Proteins are the basic building blocks of cells. They tend to be biologically active in combination with many other proteins rather than as isolated entities. Such protein complexes play a key role in many vital processes in our bodies. In the field of medicine, proteins are used, amongst other things, as antibodies for developing vaccines. One of today’s greatest challenges is to develop effective vaccines against cancer. An international team…https://www.gesundheitsindustrie-bw.de/en/article/news/designer-proteins-as-beacons-of-hope-for-pharmaceutical-and-biotechnological-applications
Article - 26/01/2017 Freiburg researchers transform skin cells into renal cells A team of researchers from Freiburg has used direct programming to successfully produce kidney-like cells very similar to natural renal tubular cells in terms of appearance and function. These cells are thus a promising alternative to kidney cells isolated from animals and cells differentiated from embryonic stem cells. The reprogrammed kidney cells can be used, for example, for pharmacological and toxicological tests and investigating the…https://www.gesundheitsindustrie-bw.de/en/article/news/freiburg-researchers-transform-skin-cells-into-renal-cells